Amgen Canada Inc. is warning of the risk of atypical femoral fracture associated with use of the osteoporosis treatment, Prolia [denosumab].

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1430, 2012-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Denosumab: A Review of its Use in the Treatment of Postmenopausal Osteoporosis

By Moen Marit D.   Keam Susan J.  

Drugs & Aging, Vol. 28, Iss. 1, 2011-01 ,pp. : 63-82

Adis International

Access to resources Recommend Favorite

The role and efficacy of denosumab in the treatment of osteoporosis: an update

By Charopoulos Ioannis   Orme Steve   Giannoudis Peter V  

Expert Opinion on Drug Safety, Vol. 10, Iss. 2, 2011-03 ,pp. : 205-217

Informa Healthcare

Access to resources Recommend Favorite

Long-term PPI use increases osteoporosis-related fracture risk

By  

Reactions Weekly, Vol. 1, Iss. 1218, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Long-term PPI use increases osteoporosis-related fracture risk

By  

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Denosumab delivers in postmenopausal osteoporosis

By  

Inpharma, Vol. 1, Iss. 1649, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite